CWI1-2 is an IGF2BP2 inhibitor that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects. In Vitro CWI1-2 (0-1 μM, 24 h) has good anti-leukemic efficacy. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Apoptosis AnalysisCell Line: MonoMac6, MOLM13 Concentration: 0-1 μM Incubation Time: 24 h Result: Induced significant cell differentiation and apoptosis in a concentration-dependent manner in IGF2BP2-high cells but not in IGF2BP2-low cells. Reduced Gln uptake and impaired mitochondrial function, resulting in reduced ATP production in AML cells. Significantly inhibited the colony-forming ability of MA9-induced leukemic mouse blasts and greatly impairs the self-renewal of LSC/LIC. In Vivo CWI1-2 (5 mg/kg, i.v., once daily, 7-10 days) can significantly delay the onset of leukemia and prolong the survival time of BMT recipient B6.SJL (CD45.1) mice without any loss in body weight . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid